Brief: Synlogic Announces Achievement Of Proof Of Concept For Synb8802 On Urinary Oxalate Lowering In Phase 1B Study

Synlogic

15/12/2022 12:06

Dec 15 (Reuters) - Synlogic Inc  SYBX.O :
    * SYNLOGIC ANNOUNCES ACHIEVEMENT OF PROOF OF CONCEPT FOR
SYNB8802
IN ENTERIC HYPEROXALURIA BASED ON URINARY OXALATE LOWERING IN
PHASE 1B STUDY
    * SYNLOGIC INC - FAVORABLE SAFETY AND TOLERABILITY, WITH
FREQUENCY
AND SEVERITY OF ADVERSE EVENTS SIMILAR ACROSS PLACEBO AND ACTIVE
ARMS
    * SYNLOGIC INC - RESULTS INCLUDE -38% REDUCTION IN URINARY
OXALATE
COMPARED TO PLACEBO IN ROUX-EN-Y GASTRIC BYPASS PATIENTS
    * SYNLOGIC INC - IN PHASE 1B SYNB8802-CP-002 STUDY, SYNB8802
DEMONSTRATED A DOSE-RELATED REDUCTION IN URINARY OXALATE
    * SYNLOGIC INC - IN ADDITION TO COMPLETED SYNB8802-CP-002
STUDY,
SYNB8802 IS ALSO BEING EVALUATED IN AN ONGOING, OUTPATIENT STUDY

Source text for Eikon:  ID:nGNX4tRXt2 
Further company coverage:  SYBX.O 
 ((Reuters.Briefs@thomsonreuters.com;))